AtriCure Inc. (ATRC): BTIG sees 73% price potential after investor day - Outlook for revenue increase to $1 billion by 2030!
Reading Time: 2 minutes
AtriCure Inc. (ATRC) is a leading medical technology company that offers innovative solutions for the treatment of atrial fibrillation (Afib) and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic, and thoracic surgeons around the globe utilize AtriCure's technologies to treat Afib, reduce Afib-related complications, and provide postoperative pain management. With the Isolator Synergy Ablation System, the company offers the first FDA-approved device for the treatment of persistent atrial...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
